ActRIIA-Fc (sotatercept analog) broadly corrected cardiopulmonary structure and function and alleviated pulmonary hypertension in experimental models of left heart disease.
Does ActRIIA-Fc improve cardiopulmonary remodeling and pulmonary hypertension in preclinical models of left heart failure?
ActRIIA-Fc (sotatercept analog) reverses pulmonary vascular remodeling and improves cardiopulmonary function in preclinical models of pulmonary hypertension due to left heart disease, supporting its clinical evaluation in PH-HFpEF.
revealed that treatment with ActRIIA-Fc prevents an abnormal, glucose-induced, activin-mediated, migratory phenotype in human pulmonary artery smooth muscle cells, providing a mechanism by which ActRIIA-Fc could exert therapeutic effects in experimental PH-HFpEF with metabolic dysregulation. Our results demonstrate that ActRIIA-Fc broadly corrects cardiopulmonary structure and function in experimental PH-LHD, including models of PH-HFrEF and PH-HFpEF, leading to alleviation of PH under diverse pathophysiological conditions. These findings highlight the important pathogenic contributions of activin-class ligands in multiple forms of experimental PH and support ongoing clinical evaluation of human ActRIIA-Fc (sotatercept) in patients with PH-HFpEF.
Joshi et al. (Thu,) conducted a other in Pulmonary hypertension in experimental left heart failure. ActRIIA-Fc (sotatercept analog) was evaluated on Cardiopulmonary structure and function. ActRIIA-Fc (sotatercept analog) broadly corrected cardiopulmonary structure and function and alleviated pulmonary hypertension in experimental models of left heart disease.